MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1063-1071

  Kryh, Hanna ^a   Abrahamsson, Jonas ^b   Jegerås, Elsa ^a   Sjöberg, Rose Marie ^a   Devenney, Irene ^c   Kogner, P E R ^d   Martinsson, Tommy ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Microhomology; Microhomology mediated break induced replication; Minimal residual disease; MYCN amplification; Neuro blastoma

Indexed keywords

DNA;

AMPLICON; ARTICLE; BLOOD; BONE MARROW; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MICROHOMOLOGY MEDIATED BREAK INDUCED REPLICATION; MINIMAL RESIDUAL DISEASE; MYCN GENE; NEUROBLASTOMA; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; BONE MARROW; CELL LINE, TUMOR; DNA; GENE AMPLIFICATION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM, RESIDUAL; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR MARKERS, BIOLOGICAL;

EID: 80053187043     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1120     Document Type: Article

References (29)

1. Maris JM and Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279, 1999. (Pubitemid 29318861)
2. Caren H, Erichsen J, Olsson L, et al: High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9: 353, 2008.
3. Michels E, Vandesompele J, Hoebeeck J, et al: Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints. Cytogenet Genome Res 115: 273-282, 2006. (Pubitemid 44832030)
4. Scott D, Elsden J, Pearson A and Lunec J: Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype? Cancer Lett 197: 81-86, 2003. (Pubitemid 36859994)
5. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
6. Corvi R, Amler LC, Savelyeva L, Gehring M and Schwab M: MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 91: 5523-5527, 1994.
7. Stark GR, Debatisse M, Giulotto E and Wahl GM: Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 57: 901-908, 1989.
8. Amler LC and Schwab M: Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. Mol Cell Biol 9: 4903-4913, 1989. (Pubitemid 19275960)
9. Hunt JD, Valentine M and Tereba A: Excision of N-myc from chromosome 2 in human neuroblastoma cells containing amplified N-myc sequences. Mol Cell Biol 10: 823-829, 1990.
10. Schwab M, Alitalo K, Klempnauer KH, et al: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248, 1983. (Pubitemid 14227614)
11. Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, Van der Schoot CE and Tytgat GA: The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma. Eur J Cancer 47: 1193-1202, 2011.
12. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem 55: 1316-1326, 2009.
13. Cheung IY, Feng Y, Gerald W and Cheung NK: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 14: 7020-7027, 2008.
14. Van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J and Van Dongen JJ: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17: 1013-1034, 2003. (Pubitemid 36722231)
15. McBride DJ, Orpana AK, Sotiriou C, et al: Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49: 1062-1069, 2010.
16. Leary RJ, Kinde I, Diehl F, et al: Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2: 20ra14, 2010.
17. Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab M and Savelyeva L: The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Hum Mol Genet 20: 1488-1501, 2011.
18. Hastings PJ, Lupski JR, Rosenberg SM and Ira G: Mechanisms of change in gene copy number. Nat Rev Genet 10: 551-564, 2009.
19. Hastings PJ, Ira G and Lupski JR: A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genet 5: e1000327, 2009.
20. Bindra RS, Schaffer PJ, Meng A, et al: Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24: 8504-8518, 2004. (Pubitemid 39245072)
21. Bacolla A, Wojciechowska M, Kosmider B, Larson JE and Wells RD: The involvement of non-B DNA structures in gross chromosomal rearrangements. DNA Repair (Amst) 5: 1161-1170, 2006. (Pubitemid 44291623)
22. Beiske K, Burchill SA, Cheung IY, et al: Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immuno-cytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100: 1627-1637, 2009.
23. Bartley PA, Ross DM, Latham S, et al: Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 32: e222-228, 2010.
24. Fleischhacker M and Schmidt B: Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 1775: 181-232, 2007. (Pubitemid 44911084)
25. Kohler C, Radpour R, Barekati Z, et al: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8: 105, 2009.
26. Diehl F, Schmidt K, Choti MA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990, 2008.
27. Fukuda M, Miyajima Y, Miyashita Y and Horibe K: Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 23: 10-13, 2001.
28. Gotoh T, Hosoi H, Iehara T, et al: Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 23: 5205-5210, 2005. (Pubitemid 46224030)
29. Kuroda T, Morikawa N, Matsuoka K, et al: Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. J Pediatr Surg 43: 2182-2185, 2008.